Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH

This study has been completed.
Sponsor:
Collaborator:
Questcor Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
NCT01155141
First received: June 29, 2010
Last updated: August 20, 2014
Last verified: August 2014
Results First Received: August 1, 2014  
Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Kidney Diseases
Intervention: Drug: H.P. Acthar Gel

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
H.P. Acthar Gel Patients treated with 40 units subcutaneously (SC) weekly for 2 weeks, 80 units SC weekly for 2 weeks, then 80 units SC twice weekly to complete 16 weeks of therapy.

Participant Flow:   Overall Study
    H.P. Acthar Gel  
STARTED     16  
COMPLETED     14  
NOT COMPLETED     2  
Withdrawal by Subject                 1  
Screen Failure                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
H.P. Acthar Gel Patients treated with 40 units subcutaneously (SC) weekly for 2 weeks, 80 units SC weekly for 2 weeks, then 80 units SC twice weekly to complete 16 weeks of therapy.

Baseline Measures
    H.P. Acthar Gel  
Number of Participants  
[units: participants]
  15  
Age  
[units: years]
Median ± Standard Deviation
  40  ± 15.1  
Gender  
[units: participants]
 
Female     6  
Male     9  
24 hour proteinuria  
[units: g/day]
Median ± Standard Deviation
  3.6  ± 5.7  
Serum Creatinine  
[units: mg/dL]
Median ± Standard Deviation
  1.4  ± 0.9  
Protein/creatinine ratio  
[units: unitless]
Median ± Standard Deviation
  3.1  ± 2.3  
Glucose  
[units: mg/dL]
Median ± Standard Deviation
  95  ± 8.4  
Weight  
[units: kg]
Median ± Standard Deviation
  87.3  ± 24.3  
Systolic blood pressure  
[units: mm Hg]
Median ± Standard Deviation
  128  ± 15.9  
Diastolic blood pressure  
[units: mm Hg]
Median ± Standard Deviation
  82  ± 9.8  
Total cholesterol  
[units: mg/dL]
Median ± Standard Deviation
  236  ± 99.5  
eGFR  
[units: mL/min/1.73m^2]
Median ± Standard Deviation
  56  ± 34.8  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   24 Hour Proteinuria   [ Time Frame: Baseline - Month 6 ]

2.  Primary:   Serum Creatinine   [ Time Frame: Baseline - Month 6 ]

3.  Primary:   Protein/Creatinine Ratio   [ Time Frame: Baseline - Month 6 ]

4.  Secondary:   eGFR   [ Time Frame: Baseline - Month 6 ]

5.  Secondary:   Weight   [ Time Frame: Baseline - Month 6 ]

6.  Secondary:   Systolic Blood Pressure   [ Time Frame: Baseline - Month 6 ]

7.  Secondary:   Diastolic Blood Pressure   [ Time Frame: Baseline - Month 6 ]

8.  Secondary:   Glucose   [ Time Frame: Baseline - Month 6 ]

9.  Secondary:   Total Cholesterol   [ Time Frame: Baseline - Month 6 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Dr. Richard Lafayette
Organization: Stanford University
phone: 650-498-6063
e-mail: czar@stanford.edu


No publications provided by Stanford University

Publications automatically indexed to this study:

Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT01155141     History of Changes
Other Study ID Numbers: SU-08182009-3600
Study First Received: June 29, 2010
Results First Received: August 1, 2014
Last Updated: August 20, 2014
Health Authority: United States: Institutional Review Board